REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $27.70.

Several equities research analysts have weighed in on the stock. Stifel Nicolaus increased their price target on shares of REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Wall Street Zen cut shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. The Goldman Sachs Group lowered their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Robert W. Baird set a $27.00 target price on shares of REGENXBIO in a report on Tuesday, February 10th. Finally, HC Wainwright cut their target price on REGENXBIO from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th.

Trending Headlines about REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Pipeline catalysts approaching — management reported that RGX‑202 (Duchenne) has topline pivotal results expected early Q2 2026, RGX‑314 (sura‑vec / wet AMD) has topline pivotal data expected Q4 2026, a pivotal Phase IIb/III diabetic retinopathy trial has started dosing, and the company plans to engage the FDA on a path forward for RGX‑121. These upcoming readouts are potential upside catalysts if data are positive. REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
• Neutral Sentiment: Company provided earnings materials and management commentary — full Q4 2025 earnings call transcripts and highlights are available for investors to review for program timelines, cash guidance and cost trajectory. Use these to reassess runway and probability of late‑stage success. REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations — REGENXBIO reported EPS of ($1.30) vs. consensus (~($0.99)) and revenue of $30.34M, highlighting continued losses and pressure on near‑term financials. The miss increases scrutiny on execution and funding assumptions ahead of costly pivotal readouts. Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Multiple law firms are soliciting lead‑plaintiff investors and reminding shareholders of an April 14, 2026 deadline in a securities class action covering Feb 9, 2022–Jan 27, 2026. The flurry of Rosen, Schall, Faruqi, Pomerantz and others’ notices signals heightened litigation risk and potential future liabilities or settlements that could pressure the stock. ROSEN, A LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX
• Negative Sentiment: Sector‑wide regulatory caution — recent FDA reversals and tougher review posture for experimental drugs are spooking investors in gene‑therapy and biotech names; this increases binary outcome risk ahead of REGENXBIO’s pivotal readouts. FDA reversals leave investors worrying about the fates of other experimental drugs

Institutional Investors Weigh In On REGENXBIO

A number of large investors have recently made changes to their positions in the business. State of Alaska Department of Revenue purchased a new position in shares of REGENXBIO during the third quarter valued at approximately $25,000. Aquatic Capital Management LLC bought a new position in shares of REGENXBIO during the third quarter valued at approximately $37,000. Jones Financial Companies Lllp lifted its stake in REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares during the period. Steward Partners Investment Advisory LLC lifted its stake in REGENXBIO by 754.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 5,000 shares during the period. Finally, Captrust Financial Advisors bought a new stake in REGENXBIO in the second quarter valued at $85,000. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Stock Performance

Shares of RGNX stock opened at $8.65 on Friday. The company has a market capitalization of $437.86 million, a P/E ratio of -2.30 and a beta of 1.08. REGENXBIO has a fifty-two week low of $5.03 and a fifty-two week high of $16.19. The stock has a 50 day moving average price of $11.47 and a two-hundred day moving average price of $11.39.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, March 12th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.31). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The firm had revenue of $30.34 million during the quarter. As a group, equities analysts predict that REGENXBIO will post -4.84 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.